Thursday, March 12, 2009

EarlySense to Partner With Catholic Healthcare West in Evaluating Patient Health With the EverOn Patient Supervision System

California Hospital Medical Center to Be First CHW Facility to Evaluate EverOn

Monday March 2, 2009, 9:01 am EST

RAMAT GAN, Israel--(BUSINESS WIRE)--EarlySense, developer of the EverOn® patient supervision system for hospital and home use, announced today a collaboration with Catholic Healthcare West (CHW), the eighth largest hospital system in the nation and the largest not-for-profit hospital provider in California, to test Everon in the hospital setting.

Select hospitals within the 41-hospital CHW system are slated to evaluate the impact of EverOn both clinically and financially to determine whether and how best to implement the technology. Based on evaluation outcomes, certain CHW facilities may elect to be training centers for the EverOn system.

EverOn is a wireless patient supervision system installed underneath the hospital bed mattress. There are no leads or cuffs to connect to the patient, who has complete freedom of movement and is not burdened by any irritating attachments. The system measures patient vital signs and movements and alerts nurses of any change in condition. EverOn detects heart and respiration rates, bed entries and exits, as well as patient movement and turns. EverOn also helps medical staff to better implement patient turns, which can positively influence the treatment and the prevention of pressure ulcers. EverOn’s trend line display is designed to assist clinicians in monitoring the progression of a patient’s health. At present, the system is for investigational use only.

“We are combining the strengths of a leading hospital system with those of a medical device innovator to facilitate the introduction of EverOn in the U.S. We believe this structure has great value as it will ultimately provide both clinical and financial benefits,” said Dr. Yehuda Zicherman, V.P. of Marketing at EarlySense.

CHW and EarlySense also announced today that California Hospital Medical Center in Los Angeles will be the first CHW clinical site to trial EverOn. Mark Meyers, president of California Hospital Medical Center, said, “There is a clear, present and immediate need for an innovative, high tech system that can automatically, and without imposing upon patient comfort, track movement and vital signs and warn of possible life threatening situations. We are pleased to be evaluating the EverOn system to determine how it can help us in our ongoing work of delivering excellent, compassionate care.”

“We are delighted and honored to partner with CHW, a well respected and notable hospital network, and its experienced and professional team at California Hospital Medical Center. We hope to together achieve the goal of improving healthcare and securing better outcomes for patients and their caregivers,” said Avner Halperin, CEO of EarlySense.

About Catholic Healthcare West:

Catholic Healthcare West (CHW), headquartered in San Francisco, CA, is a system of 41 hospitals and medical centers in California, Arizona and Nevada. Founded in 1986, it is eighth largest health system in the nation and the largest not-for-profit provider in California. CHW is committed to delivering compassionate, high-quality, affordable health care services with special attention to the poor and underserved. The CHW network of nearly 10,000 physicians and approximately 53,000 employees provides health care services to more than five million people annually. In 2008, CHW provided $967 million in charity care and unsponsored community benefit. For more information, please visit our website at www.chwHEALTH.org.

About California Hospital Medical Center:

Conveniently located in the heart of downtown Los Angeles 2 blocks from the Staples Center, California Hospital Medical Center is a 316-bed acute care hospital known for its wide range of specialties, from Orthopedics and Surgery to Maternity and Neonatal Intensive Care. It is also the area's only Level II Trauma Center. For more information, please visit http://www.chmcla.org/. Press contact: Katreena Salgado, Director, Marketing & Public Affairs, California Hospital Medical Center, katreena.salgado@chw.edu, 213-742-6371 (office) or 213-700-4774.

About EarlySense:

EarlySense is bringing to market a pioneering technology designed to advance proactive and preventive patient supervision to enable better patient outcomes. The company’s flagship product, EverOn, is an automatic, continuous, contact-free patient supervision device that follows and documents a patient’s vital signs and movement. The system is currently being clinically evaluated at several medical centers. EarlySense is headquartered in Ramat-Gan, Israel. For additional information, please visit www.earlysense.com. Press contact: Marjie Hadad, Media Liaison, at marjie.hadad@earlysense.com or at +972-54-536-5220.

Tuesday, January 27, 2009

Promius Pharma, LLC Launches Scytera (Coal Tar) Foam 2% for Treatment of Psoriasis
Scytera™ Provides Innovative Topical Coal Tar Foam in a Cosmetically Elegant, Patient-Pleasing Foam Vehicle.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Jan 26, 2009 - Promius Pharma, LLC, has launched Scytera™ (coal tar) Foam 2% for the treatment of chronic psoriasis, a skin disease that affects approximately 7.5 million Americans according to The National Psoriasis Foundation. Scytera Foam delivers coal tar in a cosmetically-elegant, patient-pleasing foam vehicle.

Scytera Foam was launched at the Winter Clinical Dermatology Conference in Hawaii in January 2009. This annual conference provides dermatologists with a comprehensive update on the diagnosis and treatment of conditions that they treat on a daily basis. Promius Pharma's mission is to once again elevate coal tar to an important position in psoriasis treatment. Studies have demonstrated that coal tar treatment of psoriasis results in a reduction in the overproduction of skin cells, a reduction of itch and a promotion of healthy skin. Scytera Foam is the first coal tar product in an aerosol foam vehicle to be launched into the psoriasis market.

"Scytera's active ingredient, coal tar, has been used for many years in the treatment of psoriasis," explained Jeffrey Wasserstein, President of Promius. "In the past, coal tar products, despite their established efficacy, have typically had usage limitations because of their unappealing odor, unpleasant texture and potential to stain clothing. We are very excited about Scytera Foam because it takes this proven therapy and marries it with a novel proprietary foam technology to address each of those three issues.” The foam technology is licensed from Foamix Ltd of Israel. “We believe Scytera Foam will be of significant benefit to dermatologists and their patients, enhancing the value and re-establishing the importance of coal tar for psoriasis treatment."

The Benefits of Scytera Foam
Scytera Foam's technology allows the product to be spread easily and smoothly over large body areas. Along with the foam technology, Scytera Foam uses a patented odor neutralizing system to minimize the coal tar odor. "Dermatologists have understood the inherent benefits of coal tar therapy for psoriasis patients for decades, but convincing patients to use it with all of the cosmetic challenges has been difficult and frustrating for physicians," said Mr. Wasserstein.

Making Coal Tar User Friendly
"Dermatologists have long acknowledged that coal tar is an excellent therapy for psoriasis that may be used alone or in combination with other psoriasis treatments under a doctor's supervision," continued Mr. Wasserstein. “Because Scytera Foam delivers coal tar in a cosmetically-appealing foam vehicle, it is our expectation that patients will be more likely to use this product. Our expectation," said Mr. Wasserstein, "is that Scytera Foam's cosmetic properties will help redefine dermatologists' perception of the downsides associated with coal tar therapy.”

Please visit www.scytera.com for more information about Scytera Foam, including usage instructions.

About Promius Pharma
Promius Pharma, LLC, located in Bridgewater, NJ, is a branded specialty company and a wholly-owned subsidiary of Dr. Reddy's Laboratories, Inc. Promius Pharma, with its focus on the branded dermatology market, has a portfolio of in-licensed dermatological products and an internal pipeline of topical products under various stages of development. Promius Pharma aims to be a leading-edge company that develops and markets innovative solutions for challenging dermatological conditions with an eye to the future to redefine therapeutic options for physicians and patients. (www.promiuspharma.com)

About Foamix Ltd.
Headquartered in Ness Ziona, Israel, Foamix Ltd. is a specialty pharmaceutical company focused on the development of topical foam products for prescription, OTC and cosmetic applications. Foamix's proprietary state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is a privately held company, whose business model is based on partnering with leading pharma companies to develop products utilizing its proprietary foam technologies. (www.foamix.co.il)Contact: Media:LC GroupSuzanne Lane, +1 212-757-6880slane@thelcgroup.com